Top ▲
Target has curated data in GtoImmuPdb
Target id: 2601
Nomenclature: CD33
Abbreviated Name: SIGLEC3
Family: Other immune checkpoint proteins, CD33-related SIGLECs, CD molecules
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 364 | 19q13.41 | CD33 | CD33 molecule | |
Mouse | 1 | 403 | 7 28.25 cM | Cd33 | CD33 molecule | |
Rat | - | - | 1q22 | Cd33 | CD33 molecule |
Previous and Unofficial Names |
CD33 antigen | SIGLEC3 |
Database Links | |
Alphafold | P20138 (Hs), Q63994 (Mm) |
CATH/Gene3D | 2.60.40.10 |
ChEMBL Target | CHEMBL1842 (Hs) |
DrugBank Target | P20138 (Hs) |
Ensembl Gene | ENSG00000105383 (Hs), ENSMUSG00000004609 (Mm), ENSRNOG00000037331 (Rn) |
Entrez Gene | 945 (Hs), 12489 (Mm), 690492 (Rn) |
Human Protein Atlas | ENSG00000105383 (Hs) |
KEGG Gene | hsa:945 (Hs), mmu:12489 (Mm), rno:690492 (Rn) |
OMIM | 159590 (Hs) |
Pharos | P20138 (Hs) |
RefSeq Nucleotide | NM_001772 (Hs), NM_001111058 (Mm) |
RefSeq Protein | NP_001763 (Hs), NP_001104528 (Mm) |
UniProtKB | P20138 (Hs), Q63994 (Mm) |
Wikipedia | CD33 (Hs) |
Download all structure-activity data for this target as a CSV file
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Evidence of the effectiveness of gemtuzumab ozogamicin centers on the drug's ability to inhibit the growth of leukemic cells in vitro and in vivo [3,6-7]. |
Immunopharmacology Comments |
CD33 (SIGLEC3) is a myeloid cell I-type (Ig-type) lectin that binds glycans containing sialic acids [4]. Most SIGLECs inhibit immune cell activation, via immunoreceptor tyrosine-based inhibitory (ITIM) motifs in their cytosolic domains. Hence, blockade of SIGLEC interactions restores immune cell activation, which is of interest for the treatment of myeloid leukemias. As such, CD33 is the target of approved monoclonal antibody-drug conjugate gemtuzumab ozogamicin (for CD33-positive acute myeloid leukemia) and investigational mAb lintuzumab which was a clinical candidate biologic for refractory or relapsed acute myelogenous leukemia. |
Cell Type Associations | ||||
|
||||
|
||||
|
Immuno Process Associations | ||
|
||
|
||
|
||
|
General Comments |
This protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590. |
1. Bernstein ID. (2000) Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia, 14 (3): 474-5. [PMID:10720144]
2. Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA. (1992) Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 52 (24): 6761-7. [PMID:1458463]
3. Frankel AE, Sievers EL, Scheinberg DA. (2000) Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother Radiopharm, 15 (5): 459-76. [PMID:11155818]
4. Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E et al.. (2005) Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood, 105 (3): 1256-64. [PMID:15388576]
5. Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP et al.. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood, 122 (8): 1455-63. [PMID:23770776]
6. McGavin JK, Spencer CM. (2001) Gemtuzumab ozogamicin. Drugs, 61 (9): 1317-22; discussion 1323-4. [PMID:11511025]
7. van Der Velden VH, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, van Dongen JJ. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97 (10): 3197-204. [PMID:11342449]
Other immune checkpoint proteins: CD33. Last modified on 15/01/2024. Accessed on 06/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2601.